BCHC Joins Opposition of Senate Bill Exempting Some Cigars from FDA Oversight
November 29, 2021
United States Senate
Washington, DC 20510
We are writing to express our opposition to S. 438, the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2021, which would exempt some cigars, including some inexpensive, machine-made cigars, from oversight under the Family Smoking Prevention and Tobacco Control Act (TCA). To fulfill its responsibility to protect public health, the Food and Drug Administration (FDA) should retain its authority over all tobacco products, including all cigars.
In 2009, Congress gave FDA authority over the manufacture, sale and marketing of all tobacco products because all tobacco products can cause serious adverse health effects. Using this authority, FDA published a final rule in 2016 that enabled the agency to begin to oversee cigars and all other tobacco products that it had not been regulating.
S. 438 would prohibit FDA from promulgating any public health protections related to what the cigar industry calls “traditional large and premium cigars,” despite the known health risks of cigar smoking. The bill defines this new category of cigar very broadly and opens the door for product manipulation to qualify for the exemption, which the industry has done before. It would specifically exempt from FDA oversight some machine-made cigars, including those that can cost as little as $1.00 to $2.00 each, and would not prohibit kid-friendly, flavored cigars from qualifying for an exemption. No cigars should be exempt from oversight, but especially not inexpensive and flavored cigars which appeal to youth and young adults.
The implications of the exemption would be far reaching. It would prevent FDA from including all cigars in a forthcoming proposed rule to prohibit flavored cigars and would exempt “traditional large and premium cigars” from a premarket review requirement that protects the public from new tobacco products that are not “appropriate for the protection of the public health.” Under this bill, even the most basic FDA requirements like ingredient disclosure and its
youth access and marketing restrictions would not apply to “traditional large and premium cigars.”
If enacted, this legislation could undercut FDA’s ability to protect youth and young adults from the health consequences of cigar smoking. Cigar smoking is not limited to adults. Nearly one million youth reported current cigar use last year. The 2020 National Youth Tobacco Survey shows that cigars are the most popular tobacco product among Black high school students and the second most popular tobacco product after e-cigarettes among all high school students. FDA
has found that, while youth and young adults tend to smoke mass market cigars, they also use premium cigars. Many youth are likely to be attracted to inexpensive, flavored cigars that could qualify as “traditional large and premium cigars” under this legislation.
Cigar smoke is composed of the same toxic and carcinogenic constituents found in cigarette smoke. According to the National Cancer Institute, cigar smoking causes cancer of the oral cavity, larynx, esophagus and lung, and cigar smokers are also at increased risk for an aortic aneurysm. Daily cigar smokers, particularly those who inhale, have an increased risk of heart disease and chronic obstructive pulmonary disease (COPD). Each year, about 9,000 Americans die prematurely from regular cigar use.
FDA should be permitted to continue to oversee all cigars. The science continues to support FDA’s conclusion in 2016 that there is no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. We are also concerned that the number of cigars exempted from FDA oversight would increase over time because S. 438 would create an incentive for cigar manufacturers to modify their products or change their manufacturing processes to qualify for the exemption.
Our organizations strongly urge you to protect public health and kids and reduce the health and economic burden of tobacco-caused disease by opposing S. 438.
Action on Smoking & Health (ASH)
African American Tobacco Control Leadership Council (AATCLC)
American Academy of Family Physicians
American Academy of Oral and Maxillofacial Pathology
American Academy of Oral and Maxillofacial Radiology
American Academy of Otolaryngology- Head and Neck Surgery (AAO-HNS)
American Academy of Pediatrics
American Association for Dental, Oral, and Craniofacial Research (AADOCR)
American Association for Respiratory Care
American Cancer Society Cancer Action Network
American College of Cardiology
American Dental Education Association
American Heart Association
American Lung Association
American Public Health Association
American Thoracic Society
Americans for Nonsmokers’ Rights
Association for Clinical Oncology
Association for the Treatment of Tobacco Use and Dependence (ATTUD)
Association of Schools and Programs of Public Health (ASPPH)
Association of State and Territorial Health Officials (ASTHO)
Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN)
Allergy & Asthma Network
Big Cities Health Coalition
Campaign for Tobacco-Free Kids
Cancer Prevention and Treatment Fund
Center for Black Equity
Center for Black Health & Equity
Community Anti- Drug Coalitions of America (CADCA)
Eta Sigma Gamma – National Health Education Honorary
International Association for the Study of Lung Cancer (IASLC)
Mesothelioma Applied Research Foundation
National Association of Pediatric Nurse Practitioners
National Association of Social Workers
National Hispanic Medical Association
National LGBT Cancer Network
Oncology Nursing Society
Pacific Islander Center of Primary Care Excellence (PI-CoPCE)
Parents Against Vaping e-cigarettes (PAVe)
Preventing Tobacco Addiction Foundation/Tobacco 21
Public Health Solutions
Society for Public Health Education (SOPHE)
Society for Research on Nicotine & Tobacco (SRNT)
The Society of Thoracic Surgeons